Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ocular Therapeutix ( (OCUL) ) has shared an announcement.
Ocular Therapeutix plans to submit a new drug application for its product candidate AXPAXLI (OTX-TKI) for wet AMD treatment based on year 1 data from its SOL-1 Phase 3 clinical trial, following recent FDA guidance. The company anticipates reporting top-line data from this trial in the first quarter of 2026, potentially accelerating its regulatory pathway and impacting its market positioning.
The most recent analyst rating on (OCUL) stock is a Hold with a $12.50 price target. To see the full list of analyst forecasts on Ocular Therapeutix stock, see the OCUL Stock Forecast page.
Spark’s Take on OCUL Stock
According to Spark, TipRanks’ AI Analyst, OCUL is a Neutral.
Ocular Therapeutix’s overall stock score is primarily impacted by its financial performance, which is currently weak due to declining revenues and persistent losses. However, the positive sentiment from the earnings call, highlighting strategic initiatives and a strong cash position, provides a counterbalance. Technical indicators show moderate bullish momentum, but valuation remains a concern due to negative earnings and lack of dividends.
To see Spark’s full report on OCUL stock, click here.
More about Ocular Therapeutix
Ocular Therapeutix operates in the ophthalmology industry, focusing on developing innovative therapies for eye diseases. The company is known for its ophthalmic product candidates, particularly targeting conditions like wet age-related macular degeneration (wet AMD).
Average Trading Volume: 2,829,789
Technical Sentiment Signal: Buy
Current Market Cap: $2.65B
For detailed information about OCUL stock, go to TipRanks’ Stock Analysis page.